Literature DB >> 11504269

Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations.

O V Olesen1, K Linnet.   

Abstract

The authors assessed the in vitro contribution of cytochrome P450 (CYP) isoforms 1A2, 3A4, 2C9, 2C19, and 2D6 to the N-demethylation of clozapine mediated by human liver microsomal preparations (HLM). In contrast to previous studies, the authors focused on a relatively low hepatic concentration level, 5 microM, to assess the conditions at a therapeutically relevant hepatic concentration level of clozapine. The optimal concentrations of specific inhibitors were initially established using cDNA-expressed CYP isoforms. The mean contributions of CYPs 1A2, 2C19, 3A4, 2C9, and 2D6 amounted to 30%, 24%, 22%, 12%, and 6%, respectively, with regard to the total HLM-mediated N-demethylation. Thus, the present in vitro study on clozapine N-demethylation suggests that CYP1A2 is the most important form at low concentrations, which is in agreement with clinical findings. CYP2C19 is also of considerable importance, while the roles of CYP2C9 and 2D6 are more modest. CYP3A4 attained a dominating role with an average contribution of 37% at a high clozapine concentration (50 microM). The rate of other metabolic routes mediated by CYP2D6 only corresponded to about one fifth of the CYP2D6 catalyzed N-demethylation rate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504269     DOI: 10.1177/00912700122010717

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  24 in total

1.  Desorption electrospray ionization mass spectrometry: Imaging drugs and metabolites in tissues.

Authors:  Justin M Wiseman; Demian R Ifa; Yongxin Zhu; Candice B Kissinger; Nicholas E Manicke; Peter T Kissinger; R Graham Cooks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

2.  A therapeutic interaction between cimetidine and clozapine: case study and review of the literature.

Authors:  Magdalena Watras; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

Review 3.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

4.  Can valproic acid be an inducer of clozapine metabolism?

Authors:  F J Diaz; C B Eap; N Ansermot; S Crettol; E Spina; J de Leon
Journal:  Pharmacopsychiatry       Date:  2014-04-24       Impact factor: 5.788

5.  Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.

Authors:  Gudrun Hefner; Mohamed E E Shams; Stefan Unterecker; Tanja Falter; Christoph Hiemke
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

Review 6.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 7.  Interactions between the cytochrome P450 system and the second-generation antipsychotics.

Authors:  Trevor I Prior; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2003-03       Impact factor: 6.186

Review 8.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Authors:  Q Xu; X Wu; M Li; H Huang; C Minica; Z Yi; G Wang; L Shen; Q Xing; Y Shi; L He; S Qin
Journal:  Pharmacogenomics J       Date:  2015-08-18       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.